Skip to main content
ALKS logo

Alkermes plc (ALKS) Stock: Price, Forecast & Analyst Target

Alkermes plc (ALKS) — MoonshotScore 35/100 (Weak band), calculated Nov 18, 2026. Price $46.18 (-1.43%), as of the Nov 19, 2026 trading session; market cap $7.76B. Expected results Feb 24, 2027.

Educational signal · not a buy or sell recommendation · How to read this

Market value / cash and short-term investments: 10.27× (cash as of Sep 30, 2026) · expected results Feb 24, 2027

$46.18 −$0.67 (-1.43%) Market Cap $7.76B

Alkermes plc · ALKS · NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic

Research dated 2026-09-13: Alkermes commercializes proprietary medicines for addiction and neuropsychiatric disorders while also earning manufacturing and royalty revenue from technology-platform relationships. Vivitrol, Aristada, Aristada Initio and Lybalvi must produce durable commercial economics while research spending rises and debt remains above available cash and investments.

Price as of Nov 19, 2026

Key Statistics

35 of 100

MoonshotScore v2 · Alkermes (ALKS)

Weak
Business Quality Solid (79)
Financial Safety Fragile (13)
Valuation Full (43)
Growth Durability Flat (46)
Momentum Surging (84)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

High quality, but a fragile balance sheet — yet price is running hot, well ahead of those stalled fundamentals; treat the move with suspicion, not chase. The score also carries a risk penalty for losses on top of negative retained earnings. Business Quality: Solid; Financial Safety: Fragile; Valuation: Full; Growth Durability: Flat; Momentum: Surging.

  • EPS beat 3 of the last 4 reports
  • Altman Z 2.26 · Piotroski F 2
  • ROE -0.0% · ROA -0.0% · current ratio 2.42 · earnings yield -0.0% · free-cash-flow yield 3.0%

Holding back: balance-sheet strain

Helping: business quality, positive momentum

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for ALKS (52 recorded, newest six shown)
RecordedScoreBand
38Weak
36Weak
36Weak
36Weak
35Weak
35Weak

Daily score refresh is delayed. This is the last recorded calculation.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · How the MoonshotScore is computed →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$46.18
Change on the day-1.43%
52-week range$27.00–$55.67
Market capitalisation$7.76B—
Price / earnings (trailing)111.39
Shares traded on the day1.37M
Beta (volatility vs the S&P 500)0.27

Price & events

Weekly closing price with reported quarters marked Weekly closing price from Oct 17, 2025 to Nov 19, 2026: low $28, high $55, latest $46. 4 reported quarters marked, 3 above and 1 below the recorded estimate. 1 other dated event marked. $55 $28 high $55 Feb 25, 2026 · Earnings results · reported below the recorded estimate · close $301May 5, 2026 · Earnings results · reported above the recorded estimate · close $352Jul 28, 2026 · Earnings results · reported above the recorded estimate · close $493Nov 3, 2026 · Earnings call · management outlook · no recorded estimate to compare · close $464Nov 3, 2026 · Earnings results · reported above the recorded estimate · close $465 Oct 17, 2025 Nov 19, 2026 · $46 $30Oct 17, 2025$31Oct 31, 2025$29Nov 14, 2025$30Nov 28, 2025$29Dec 12, 2025$28Dec 26, 2025$30Jan 9, 2026$34Jan 23, 2026$35Feb 6, 2026$32Feb 20, 2026$29Mar 6, 2026$28Mar 20, 2026$35Apr 2, 2026$35Apr 17, 2026$33May 1, 2026$37May 15, 2026$42May 29, 2026$44Jun 12, 2026$55Jun 26, 2026$52Jul 10, 2026$53Jul 24, 2026$49Aug 7, 2026$48Aug 21, 2026$46Sep 4, 2026$43Sep 18, 2026$42Oct 2, 2026$41Oct 16, 2026$45Oct 30, 2026$47Nov 13, 2026

Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file or a dated event that is not a results report. Numbers key to the dated list. Point at or tab to any week for its close.

Events behind the price

  • · Earnings results · below the recorded estimate
  • · Earnings results · above the recorded estimate
  • · Earnings results · above the recorded estimate
  • · Earnings call · management outlook
  • · Earnings results · above the recorded estimate

Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.

Upcoming events

As of

  1. Next results dueProvider estimate

Management outlook

  • For the full year, we continue to expect VIVITROL net sales in the range of $460 million to $480 million.

    Christian Todd Nichols · Statement from

  • For the full year, we continue to expect ARISTADA net sales in the range of $365 million to $385 million LYBALVI net sales were $95.9 million in the third quarter.

    Christian Todd Nichols · Statement from

How to read these dates

A statement's date is the earnings call where it was made, not a deadline. Management expectations and estimated dates can change.

Read management statements

Other perspectives

Council score for Alkermes (ALKS): perspectives

Some lenses disagree with the MoonshotScore. Compare their readings below; each uses a different method.

5-Factor Breakdown

Business Quality Moderate
Financial Safety Negative
Valuation Neutral
Growth Durability Neutral
Momentum Strong

Legends Council

4 lenses, 4 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Englander-style lens (simulated) Izzy Englander Neutral read
Klarman-style lens (simulated) Seth Klarman Favorable read
Moon AI lens (model) Favorable read

Read on: Nov 19, 2026

Munger's Mindset

Balance Sheet & Valuation

Financial Health Weak
Margin of Safety Fairly Valued
Profit Margin Weak
Debt/Equity Weak
ROE Negative
Gross Margin Strong

Read on: Nov 19, 2026

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

Three of these lenses read this company more favourably than the MoonshotScore does: Dalio-style lens, Klarman-style lens and Moon AI lens. Each lens is a separate scoring function over its own inputs, so a disagreement is a difference of method rather than a correction — the page's answer stays the MoonshotScore above.

The Munger lens reads the current price as fairly valued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is Alkermes (ALKS), and what does it report?

Short answer · as of

Alkermes is not a conventional generic-drug manufacturer. Its reported revenue blends sales of named proprietary treatments with manufacturing, manufactured-product and royalty income connected to technology platforms and pharmaceutical collaborations.

That mix matters because consolidated revenue does not measure demand for a lone medicine or pipeline progress alone. It combines commercial performance in addiction and serious mental illness with partner-related economics, while research spending reflects continued work on neurological candidates.

2 · Latest results

What do the latest results show for Alkermes (ALKS)?

The latest reported period delivered the strongest revenue in the presented quarterly series, reversing the preceding operating loss and returning the business to a modest profit. Operating cash flow also swung back into positive territory, while revenue and reported earnings exceeded analyst expectations.

The rebound coincided with selling and administrative expense retreating from its prior spike, even as research spending continued to rise. That expense pattern helped restore operating profitability, but the narrow net result shows that stronger revenue did not translate into a comparably large bottom-line cushion.

Where is operating spending going?

Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.

Latest quarter · revenue
$480.13M Sep 30, 2026
Latest quarter · R&D
$121.12M Sep 30, 2026
Latest quarter · SG&A
$208.50M Sep 30, 2026
Latest quarter · FMP standardized operating result
$36.02M Sep 30, 2026
Period endRevenueR&DSG&AFMP standardized operating result
Sep 30, 2026$480.13M$121.12M$208.50M$36.02M
Jun 30, 2026$496.01M$112.92M$217.60M$18.38M
Mar 31, 2026$392.91M$103.34M$264.59M−$48.28M
Dec 31, 2025$384.55M$93.04M$190.50M$58.10M
How to read these figures

Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.

Did results meet expectations?

Reported earnings and revenue alongside the estimates recorded by the provider.

Latest report · revenue
$480.13M Nov 3, 2026
Latest report · revenue estimate
$463.48M Nov 3, 2026
Latest report · revenue vs estimate
Above estimate Nov 3, 2026
Latest report · EPS vs estimate
Above estimate Nov 3, 2026
Report dateRevenue · reportedRevenue · estimateEPS · reportedEPS · estimate
Nov 3, 2026$480.13M$463.48M$0.0900−$0.0818
Jul 28, 2026$496.01M$457.38M$0.7000−$0.0274
May 5, 2026$392.91M$363.06M−$0.4000−$0.5700
Feb 25, 2026$384.55M$378.94M$0.3400$0.4300
How to read these figures

Dates are when results were reported, not quarter ends. Amounts are in US dollars; EPS is per share. The source does not say whether EPS is basic, diluted or adjusted, so it can differ from the EPS in the income statement.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Jun 2025$391M$87M$0.52 (diluted)
Sep 2025$394M$83M$0.49 (diluted)
Q4 FY2025$385M$49M$0.29 (diluted)
Q1 FY2026$393M-$66M-$0.40 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for Alkermes (ALKS)?

Short answer

Cash and short-term investments were $755.46M at the Sep 30, 2026 balance-sheet date. Operating cash flow was $93.48M for the quarter ended Sep 30, 2026, meaning operations generated cash. These figures do not establish a cash runway.

High gross profitability and recurring positive operating cash flow provide meaningful internal funding capacity, and capital expenditure has remained modest relative to operating cash generation. Near-term liquidity ratios also indicate resources available against current obligations.

The balance sheet still carries substantially more debt than cash and investments, leaving Alkermes in a net-debt position. Cash has fallen sharply from its recent peak, profitability has been volatile, and rising research expense increases the damage that weaker sales from Vivitrol, Aristada or related commercial lines could cause to operating results.

Data-derived red flags

  • Negative return on equity (-0.0%) — the business is not currently generating profit on shareholder capital.
  • Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
  • Rich valuation — a P/E of 111.39 runs well above the Healthcare sector’s ~21.70x, leaving little room for a miss.

How much cash does the business generate or use?

Quarterly operating cash flow shows cash generated or used by operations.

Latest quarter · operating cash flow
$93.48M Sep 30, 2026
Previous quarter · operating cash flow
$145.18M Jun 30, 2026
Period endOperating cash flowCapital expenditure (reported)
Sep 30, 2026$93.48M−$3.40M
Jun 30, 2026$145.18M−$8.15M
Mar 31, 2026−$165.74M−$4.09M
Dec 31, 2025$170.07M$20,000
How to read these figures

Amounts are in US dollars. Negative operating cash flow means the business used cash. Capital spending is shown as reported; we do not combine it into a free-cash-flow or runway estimate. The bars share one scale.

4 · What to check next?

What should you watch next at Alkermes (ALKS)?

Short answer · as of

The next earnings report is expected on Feb 24, 2027.

The next earnings release needs to establish whether revenue can remain near its recent high, operating profit can stay positive and operating cash flow can avoid another reversal. Research spending, the normalization of selling and administrative expense, and the cash balance deserve attention because recent movements in those lines have been unusually large.

Longer-range analyst estimates embed sustained revenue and earnings expansion, making progress across the proprietary portfolio more important than an isolated earnings beat. Any disclosed financial or strategic effects from the recently reported material definitive agreement also warrant attention.

What management is planning

Management expectations, not completed milestones or guarantees. Selected verbatim excerpts; dates follow the transcript provider.

  1. For the full year, we continue to expect LYBALVI net sales in the range of $380 million to $400 million Looking ahead to next year, we expect gross to net adjustments for LYBALVI to be in the 45% range. We expect the benefits of expanded payer access to be reflected first in prescription volume, which we expect will continue to grow nearly 20% year-over-year with an acceleration in net sales growth expected to follow.

    Christian Todd Nichols ·

  2. For the full year, we continue to expect total LUMRYZ net sales of $350 million to $370 million of which Alkermes expects to record $315 million to $335 million reflecting the mid February close of the Avadel transaction.

    Christian Todd Nichols ·

2 more statements are quoted under Upcoming events

5 · Peer comparison

How does Alkermes compare with its peers?

Short answer

Alkermes's score ranks tied for 11th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.

Alkermes differs from a development-stage biotechnology company because marketed products already generate substantial revenue and operating cash flow. It also differs from a broad generic manufacturer: its economics are tied to branded treatments in addiction and serious mental illness, supplemented by manufacturing and royalty relationships built around proprietary technology platforms.

The resulting profile combines branded-drug gross profitability with the research intensity and earnings volatility associated with an active neurological pipeline. That combination makes commercial execution and development spending inseparable when assessing operating durability.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
Lantheus Holdings, Inc. (LNTH) Same industry, near in market value$102.00 Nov 18, 2026$6.67B96 5-pillar Nov 18, 2026
TG Therapeutics, Inc. (TGTX) Named competitor$66.12 Nov 18, 2026$9.99B90 5-pillar Nov 18, 2026
Protagonist Therapeutics, Inc. (PTGX) Named competitor$127.16 Nov 18, 2026$8.30B88 5-pillar Nov 18, 2026
Zoetis Inc. (ZTS) Same industry, near in market value$85.57 Nov 18, 2026$34.8B87 5-pillar Nov 18, 2026
Dr. Reddy's Laboratories Limited (RDY) Same industry, near in market value$14.85 Nov 19, 2026$12.4B77 5-pillar Nov 18, 2026
Supernus Pharmaceuticals, Inc. (SUPN) Same industry, near in market value$28.96 Nov 18, 2026$6.02B74 5-pillar Nov 18, 2026
HUTCHMED (China) Limited (HCM) Same industry, near in market value$13.99 Nov 18, 2026$2.43B70 5-pillar Nov 18, 2026
Amneal Pharmaceuticals, Inc. (AMRX) Same industry, near in market value$21.88 Nov 18, 2026$7.62B66 5-pillar Nov 18, 2026
Vaxcyte, Inc. (PCVX) Named competitor$58.52 Nov 18, 2026$9.26B51 5-pillar Nov 18, 2026
Regencell Bioscience Holdings Limited (RGC) Same industry, near in market value$4.69 Nov 18, 2026$2.33B47 5-pillar Nov 18, 2026
Alkermes (ALKS) — this page$46.18$7.76B35
Elanco Animal Health Incorporated (ELAN) Same industry, near in market value$26.70 Nov 18, 2026$13.4B35 5-pillar Nov 18, 2026
Viatris Inc. (VTRS) Same industry, near in market value$20.28 Nov 18, 2026$23.3B35 5-pillar Nov 18, 2026

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

Screen more Healthcare stocks

The records behind this page

Analyst targets & estimates

What analysts have on file

Price target, low to high
$50.00 – $68.00
Consensus target
$58.70
Median target
$58.50

Consensus record · Captured .

Measured against a quoted price of $46.18 (as of Nov 19, 2026).

Insider activity

Form 4 records via FMP · Of the newest 500 records, those within the last 180 days, newest dated Nov 3, 2026

Transactions
40
Identified insiders
9
Purchases
0
Sales
16
Other transactions
24

Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.

Who holds the shares?

Institutional ownership reported through 13F filings.

Reporting holders
426 Period end Sep 30, 2026
Previous quarter · holders
439 Prior to period end Sep 30, 2026
Holders in provider snapshotShares
Blackrock, INC.28,703,354
State Street Corp10,131,249
Baker Bros. Advisors LP10,012,267
Vanguard Portfolio Management LLC9,459,289
Vanguard Capital Management LLC7,503,336

Tracked investors

Which of the 16 named investors we follow held ALKS in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported ALKS in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Holder snapshot as of Sep 30, 2026. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about Alkermes (ALKS)?

Read these with our analysis →

What Investors Ask About Alkermes (ALKS) — Healthcare

The last 2 questions are answered from this page's own dated data, not from the research.

How do Vivitrol and Aristada shape Alkermes revenue?

Vivitrol is the largest disclosed product revenue category, while Aristada and Aristada Initio form another major proprietary franchise. Their weight makes Alkermes sensitive to commercial performance in addiction treatment and schizophrenia alongside its partner-related revenue streams.

Why does Alkermes report manufacturing and royalty revenue alongside medicine sales?

Alkermes provides proprietary technology platforms to pharmaceutical partners and maintains collaboration relationships. Those arrangements create manufacturing, manufactured-product and royalty economics beyond sales of Alkermes-branded medicines.

What changed in Alkermes after its recent operating loss?

Revenue rose to the strongest level in the presented quarterly series, the operating result returned to profit and operating cash flow recovered. Selling and administrative expense receded from its prior surge, although research spending continued upward.

Does Alkermes cash cover its debt?

Cash and investments remain below total debt, leaving the company in a net-debt position. Current liquidity is supported by positive short-term ratios, but the cash balance has declined materially from its recent peak.

What is the ALKS stock price today?

The last price recorded for Alkermes plc (ALKS), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What is the ALKS price target?

The analyst consensus price target for Alkermes plc (ALKS), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.

Research written by Codex (gpt-5.6-sol) on 2026-09-13. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 79 figures on this page — 2 from SEC filings and earnings calls, 70 from Financial Modeling Prep (FMP), 3 with no recorded source, 3 computed by us, formula shown in the register and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections

Sources (as of 2026-09-13), by section of the research

  • Summary at the top of the page: Business description; Revenue by segment; Quarterly income statement (USD thousands); Annual revenue and net result (USD millions); Cash, investments and debt
  • 1. What is Alkermes (ALKS), and what does it report?: Sector / industry (provider taxonomy); Business description; Revenue by segment; Annual revenue and net result (USD millions)
  • 2. What do the latest results show for Alkermes (ALKS)?: Quarterly income statement (USD thousands); Operating cash flow by quarter (USD millions); Reported versus estimated, last 8 quarters
  • 3. What are the financial strengths and risks for Alkermes (ALKS)?: Trailing twelve-month ratio set; Operating cash flow by quarter (USD millions); Cash, investments and debt; Cash and investment components; Cash and short-term investments over time (USD millions); Cash decline over the reported window; Cash against market value; Quarterly income statement (USD thousands); Revenue by segment
  • 4. What should you watch next at Alkermes (ALKS)?: Next earnings report; Analyst revenue and earnings estimates (average); Reported versus estimated, last 8 quarters; Quarterly income statement (USD thousands); Operating cash flow by quarter (USD millions); Cash and short-term investments over time (USD millions); Recent SEC filings
  • 5. How does Alkermes compare with its peers?: Business description; Sector / industry (provider taxonomy); Revenue by segment; Trailing twelve-month ratio set; Annual revenue and net result (USD millions); Quarterly income statement (USD thousands); Operating cash flow by quarter (USD millions)
  • FAQ: How do Vivitrol and Aristada shape Alkermes revenue?: Business description; Revenue by segment
  • FAQ: Why does Alkermes report manufacturing and royalty revenue alongside medicine sales?: Business description; Revenue by segment
  • FAQ: What changed in Alkermes after its recent operating loss?: Quarterly income statement (USD thousands); Operating cash flow by quarter (USD millions); Reported versus estimated, last 8 quarters
  • FAQ: Does Alkermes cash cover its debt?: Cash, investments and debt; Cash and investment components; Cash against market value; Cash and short-term investments over time (USD millions); Trailing twelve-month ratio set
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.

ETFs that hold ALKS

Funds in our ETF coverage that list ALKS among the top 10 holdings on their fund page, largest weight first. Each weight is the fund's reported holding weight as of the date in its row.

ETFWeightHoldings as of
iShares Neuroscience and Healthcare ETF (IBRN)4.21%